Lilly Asia Ventures
Ting Feng, Ph.D., is a Vice President with Lilly Asia Ventures (LAV). Prior to joining LAV, Ting was a Senior Investment Manager at SAIF Partners, focusing on healthcare investment in China. Prior to SAIF, Ting worked as a Senior Consultant at IMS Consulting Group and postdoctoral fellow at Harvard Medical School. Ting holds a Ph.D. in Immunology from University of Alabama at Birmingham and B.S. in Biotechnology from Wuhan University.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.